Document text
Principal Investigator: Jordan Green
Organization: JOHNS HOPKINS UNIVERSITY
Fiscal Year: 2024
Award: $284,285
Funding agency: National Institute of Biomedical Imaging and Bioengineering
TR&D2 Abstract
The goal of TR&D #2 is to bioengineer nanoimmunomaterial tools (NIMs) through the design and synthesis of
new biomaterials and nanoparticles (NPs) created for immunomodulation. This TR&D is driven by the needs of
CPs and SPs for safe, effective, and targeted tools to genetically manipulate immune cells ex vivo and in vivo.
Specifically, we will engineer NIMs’ chemical structure, physical properties, and surface coating with biologics
to maximize cell-specific intracellular delivery of nucleic acids to program immune cells. TR&D #2 focuses on
genetically engineering three specific types of immune cells (dendritic cells, macrophages, and T cells),
including applications to stimulate or suppress reactivity to antigens in vivo in a targeted, cell-specific fashion.
NIMs will be evaluated for applications to human health, including oncology and autoimmunity. NIMs will be
made available to be utilized as an enabling technology by the other TR&Ds as the NIMs are synthesized,
characterized, and validated. Additionally, the NIMs will be made available to CP collaborators, SP projects,
and the broader bioengineering and immunology communities as tools for investigators to further their own
research goals. TR&D2 supports and aligns with the Johns Hopkins Translational ImmunoEngineering (JH-TIE)
vision in its use of engineering principles (Chemical Engineering, Materials Science & Engineering, and
Biomedical Engineering) to design enabling immunoengineering technology and advance immunotherapy.
Terms: <Adjuvant><Amines><Antigen Targeting><Antigen-Presenting Cells><Antigens><Antineoplastic Vaccine><Autoimmune Status><Autoimmunity><Binding><Biocompatible Materials><Biodistribution><Biological><Biological Agent><Biological Products><Biomaterials><Biomedical Engineering><Body Tissues><Cancer Model><Cancer Vaccines><CancerModel><Capsid Proteins><Cell Body><Cell Surface Proteins><Cells><Chemical Engineering><Chemical Structure><Chemicals><Chemistry><Coat Proteins><Communities><Custom><DNA><Dendritic Cells><Deoxyribonucleic Acid><Disseminated Sclerosis><Drug Kinetics><EAE><Engineering><Esters><Experimental Allergic Encephalitis><Experimental Allergic Encephalomyelitis><Experimental Autoimmune Encephalitis><Experimental Autoimmune Encephalomyelitis><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Formulation><Gene Delivery><Genetic Algorithm><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genetic Programming><Germinoblastic Sarcoma><Germinoblastoma><Goals><Health><Human><Hydrophobicity><Immune><Immune Targeting><Immune mediated therapy><Immunes><Immunity><Immunologically Directed Therapy><Immunology><Immunomodulation><Immunotherapy><In Situ><In Vitro><Injections><Investigators><Kinetics><Libraries><Ligands><Lipids><Lymphoma><Macrophage><Malignant Lymphoma><Malignant Melanoma><Maps><Melanoma><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Multiple Sclerosis><Murine><Mus><Mφ><Neoplasm Vaccines><Nucleic Acids><Oncology><Oncology Cancer><Particle Size><Pharmacokinetics><Polymers><Production><Property><Protein Engineering><Reagent><Recombinant DNA Technology><Reporter><Research><Research Personnel><Researchers><Reticulolymphosarcoma><Role><Safety><Sight><Specificity><Spleen><Spleen Reticuloendothelial System><Structure><Surface><System><T-Cells><T-Lymphocyte><Technology><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Transfection><Tumor Antigens><Tumor Vaccines><Tumor-Associated Antigen><Veiled Cells><Viral Coat Proteins><Viral Outer Coat Protein><Vision><accessory cell><amine><anti-tumor vaccine><antigen-specific T cells><autoimmune encephalomyelitis><bio-engineered><bio-engineers><bioengineering><biologic><biological engineering><biological material><biologics><biopharmaceutical><biotherapeutic agent><cancer antigens><customs><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><design><designing><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><engineered T cells><engineered immune system><evaluate efficacy><examine efficacy><flow cytophotometry><gene manipulation><genetic manipulation><genetic protein engineering><genetic vaccine><genetically engineered><genetically engineered T-cells><genetically manipulate><genetically perturb><immune engineering><immune modulation><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoengineering><immunogen><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><improved><in vivo><insular sclerosis><lipophilicity><mRNA><materials science><nano particle><nano polymer><nano-sized particle><nanocarrier><nanomaterials><nanoparticle><nanopolymer><nanosized particle><nanovessel><new vaccines><next generation vaccines><novel vaccines><nucleic acid delivery><particle><physical property><polymer><polymeric><programs><protein design><site targeted delivery><social role><surface coating><synergism><targeted delivery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><thymus derived lymphocyte><tool><transgenic T- cells><tumor-specific antigen><uptake><vaccine efficacy><vaccine for cancer><visual function>